Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: initial experience with intracoronary tenecteplase.
Kelly RV, Crouch E, Krumnacher H, Cohen MG, Stouffer GA.
Catheter Cardiovasc Interv. 2005 Nov;66(3):327-32. doi: 10.1002/ccd.20521.
Intracoronary arterial retrograde thrombolysis with percutaneous coronary intervention: a novel use of thrombolytic to treat acute ST-segment elevation myocardial infarction.
Tian JW, Zhu M, Wang FQ, Li K, Zhou CF, Li B, Wang M, Deng JL, Jiang B, Bai J, Guo Y, Jin RJ, Zhang Z, Lin Y, Wang JH, Zhao SH, Shen MZ.
J Geriatr Cardiol. 2019 Jun;16(6):458-467. doi: 10.11909/j.issn.1671-5411.2019.06.004.
Intracoronary injection of tirofiban prevents microcirculation dysfunction during delayed percutaneous coronary intervention in patients with acute myocardial infarction.
Sun Z, Zeng J, Huang H.
Int J Cardiol. 2016 Apr 1;208:137-40. doi: 10.1016/j.ijcard.2016.01.204. Epub 2016 Jan 23.
Kounis syndrome with Samter-Beer triad treated with intracoronary adrenaline.
Ihdayhid AR, Rankin J.
Catheter Cardiovasc Interv. 2015 Nov 15;86(6):E263-7. doi: 10.1002/ccd.25960. Epub 2015 Aug 10.
Efficacy and safety of intracoronary pro-urokinase injection during percutaneous coronary intervention in treating ST elevation myocardial infarction patients: a systematic review and meta-analysis of randomized controlled trials.
Yin XS, Huang YW, Li ZP, Dong JL, Zou JM, Tian L, Yang J.
Eur Rev Med Pharmacol Sci. 2022 Aug;26(16):5802-5813. doi: 10.26355/eurrev_202208_29518.
Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: A meta-analysis of randomized controlled trials.
Sun B, Liu Z, Yin H, Wang T, Chen T, Yang S, Jiang Z.
Medicine (Baltimore). 2017 Oct;96(40):e8223. doi: 10.1097/MD.0000000000008223.
[Effect of intracoronary tirofiban combined with nitroprusside injection through thrombus aspiration catheter during primary percutaneous coronary intervention on acute anterior myocardial infarction patients with heavy thrombosis burden].
Zhang D, Wang L, Du J, Wang H, Xu L, Li W, Ni Z, Xia K, Liu Y, Yang X.
Zhonghua Xin Xue Guan Bing Za Zhi. 2014 Jan;42(1):25-30.
Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G.
Circulation. 2008 Jul 1;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642. Epub 2008 Jun 16.
Safety and efficacy of intracoronary prourokinase administration in patients with high thrombus burden.
Wang X, Liu H, Wu H, Xiao Y, Bai S, Li X, Li X, Zhang L, Chen T, Li H, Liu J, Du R.
Coron Artery Dis. 2020 Sep;31(6):493-499. doi: 10.1097/MCA.0000000000000853.
The influence of intracoronary injection of bone marrow cells on prothrombotic markers in patients with acute myocardial infarction.
Solheim S, Seljeflot I, Lunde K, Bratseth V, Aakhus S, Forfang K, Arnesen H.
Thromb Res. 2012 Nov;130(5):765-8. doi: 10.1016/j.thromres.2011.11.045. Epub 2011 Dec 20.
